ライフサイエンスコーパス: conjugate vaccine

1 of the countries that introduced the group A conjugate vaccine.

2 n optimum oligosaccharide for inclusion in a conjugate vaccine.

3 mice similarly immunized with an irrelevant conjugate vaccine.

4 tudy the impact of the 7-valent pneumococcal conjugate vaccine.

5 us toxoid conjugate providing a tricomponent conjugate vaccine.

6 No benefit was seen after pneumococcal conjugate vaccine.

7 oly)glycerolphosphate for potential use in a conjugate vaccine.

8 Burkina Faso before the introduction of NmA conjugate vaccine.

9 MH7) or a control keyhole limpet hemocyanin conjugate vaccine.

10 ific IgG responses to a soluble pneumococcal conjugate vaccine.

11 meningococcal group C polysaccharide-protein conjugate vaccine.

12 011, before the introduction of pneumococcal conjugate vaccine.

13 he now-licensed, highly effective MenAfriVac conjugate vaccine.

14 th age but not by serotypes in the different conjugate vaccines.

15 mperative to the immunological properties of conjugate vaccines.

16 capacity to afford the cost of conventional conjugate vaccines.

17 he T-cell-dependent response associated with conjugate vaccines.

18 n prevention of TH2 responses by flagellin A conjugate vaccines.

19 of serotypes covered by current pneumococcal conjugate vaccines.

20 responses to both protein and polysaccharide conjugate vaccines.

21 teins to provide glycoconjugate antigens and conjugate vaccines.

22 cal polysaccharide or polysaccharide-protein conjugate vaccines.

23 es suggest new approaches to novel synthetic conjugate vaccines.

24 he development of low-price supply lines for conjugate vaccines.

25 broad-ranging Salmonella lipopolysaccharide conjugate vaccines.

26 sh the design principles for improved glycan conjugate vaccines.

27 lude vaccine strategies with the new typhoid conjugate vaccines.

28 sess the key characteristics of conventional conjugate vaccines.

29 Pneumococcal conjugate vaccine 10 (PCV10) and pneumococcal conjugate

30 onjugate vaccine 10 (PCV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in childhood immu

31 tion compared with the 7-valent pneumococcal conjugate vaccine (7vCRM) in young children.

32 s found, most used the 7-valent pneumococcal conjugate vaccine (7vCRM).

33 Carbohydrate conjugate vaccines achieve this by coupling bacterial po

34 The conjugate vaccine against serogroup A Neisseria meningit

35 oxic, CRM197 is an ideal carrier protein for conjugate vaccines against encapsulated bacteria and is

36 bacterial disease after the introduction of conjugate vaccines against H influenzae, N meningitidis,

37 Widespread vaccination with conjugate vaccines against Haemophilus influenzae and St

38 f immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adul

39 Meningococcal conjugate vaccines against serogroups A, C, W, and Y (Me

40 ive strategies, including the polysaccharide conjugate vaccines, aim to eliminate asymptomatic carria

41 e 13 serotypes included within the 13-valent conjugate vaccine and 8 additional key serotypes or sero

42 er of a Hib-serogroup C meningococcal (MenC) conjugate vaccine and again 1 week, 1 month, and 1 year

43 ogroup level, including all of the 13-valent conjugate vaccine and other replacement serotypes.

44 and to consider the effects of pneumococcal conjugate vaccine and rotavirus vaccine in the estimatio

45 combined Haemophilus influenzae type b-MenC conjugate vaccine and then 1 wk, 1 mo, and 1 y after the

46 an for the development of new group A or A/C conjugate vaccines and explored the feasibility of devel

47 ce racial disparities in IPD, higher valency conjugate vaccines and strategies to directly address un

48 ortality associated with the introduction of conjugated vaccines and a mortality decrease that is ass

49 erotypes contained in 13-valent pneumococcal conjugate vaccine, and evaluated determinants for IgG >/

50 ed with pneumococcal capsular polysaccharide conjugate vaccine, and then sequentially coinfected 5 we

51 e immunized with combinations of CP and PNAG conjugate vaccines, and in serum samples of healthy subj

52 following infant priming with 3 doses of Hib conjugate vaccine, anti-PRP IgG geometric mean concentra

53 not contained in the 13-valent pneumococcal conjugate vaccine (AOR, 1.70; 95% CI, .30-9.76; P = .55)

54 Conjugate vaccines are an effective way to create a long

55 New conjugate vaccines are imminent and new treatments have

56 Pneumococcal conjugate vaccines are important tools in the approach t

57 olysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from

58 Conjugate vaccine-associated indirect protection for adu

59 erstand and model the impact of pneumococcal conjugate vaccines at the population level, we need to k

60 ons recommended that a group A meningococcal conjugate vaccine be developed and introduced into the A

61 lf-life extension, antibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell thera

62 the CP5-cross-reactive material 197 (CRM197) conjugate vaccine bound only to purified CP5.

63 gy it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale.

64 Conjugate vaccines can harness alternative help to activ

65 in humans and animals and two hexasaccharide conjugate vaccine candidates that produce high levels of

66 r antibody response when vaccinated with the conjugate vaccine compared with the pneumococcal polysac

67 synthetic scheme was devised for preparing a conjugate vaccine composed of the Bordetella bronchisept

68 These deficiencies are addressed by conjugate vaccines composed of bacterial polysaccharide

69 hat protective antibodies may be elicited by conjugate vaccines composed of tri and tetrasaccharide e

70 by a meningococcal serogroup C PS (Men C)-TT conjugate vaccine conform to the isotype-switched (IgG(+

71 hemically partially deacetylated PNAG, three conjugate vaccines consisting of 9GlcNH(2) conjugated to

72 A conjugate vaccine containing Haemophilus influenzae type

73 from clinical trials, strongly suggest that conjugate vaccines containing TT such as PsA-TT should b

74 sibly be mitigated by vaccination with a GBS conjugate vaccine currently under clinical development.

75 Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series with

76 Lipooligosaccharide (LOS) based conjugate vaccines derived from individual serotype M. c

77 he intact virus represents a step forward in conjugate vaccine design because it provides multiple an

78 ction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis b

79 Importantly, the PMA-FLA conjugate vaccine did not elicit antibodies that neutral

80 had not, respectively, received a fourth Hib conjugate vaccine dose (mean age, 3.9 years).

81 n 2-30 months old in a 7-valent pneumococcal conjugate vaccine dosing trial.

82 PV), and Haemophilus influenzae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children within t

83 s the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type s

84 Such "conjugate vaccines" efficiently induce antibody avidity

85 which impact was attributed to pneumococcal conjugate vaccines, either as efficacy or effectiveness.

86 ted a remarkable ability to adapt during the conjugate vaccine era.

87 or young children and/or serogroup C or ACWY conjugate vaccine for adolescents.

88 ose typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine for persons >/=6 months of age.

89 and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan Africa.

90 Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.

91 A 13-valent pneumococcal conjugate vaccine has been studied in adults aged >/= 50

92 A group A meningococcal (MenA) conjugate vaccine has progressively been introduced in t

93 Early evidence suggests the conjugate vaccine has substantially reduced the rate of

94 d use of Haemophilus influenzae type b (Hib) conjugate vaccines has nearly eradicated invasive Hib di

95 Capsular polysaccharide conjugate vaccines have been tested in phase I/II clinic

96 Pneumococcal conjugate vaccines have had unprecedented success in con

97 Polysaccharide-protein conjugate vaccines have proven to be highly effective ag

98 roup C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administered in the lef

99 e (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT).

100 d after the introduction of the pneumococcal conjugate vaccine in 2006: hospital admission rates in 2

101 e introduction of the 13-valent pneumococcal conjugate vaccine in 2011.

102 en contrasted with keyhole limpet hemocyanin conjugate vaccine in a subsequent experiment (n = 16), w

103 ed persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advisory Committee

104 endations for widespread use of pneumococcal conjugate vaccine in low-income and middle-income countr

105 serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2000 were driv

106 of goods" to develop a group A - containing conjugate vaccine in the United States would be in the r

107 5 and CP8, the immunogenicity of CP5 and CP8 conjugate vaccines in mice and rabbits was evaluated by

108 With the success of pneumococcal and Hib conjugate vaccines in reducing the risk of meningitis am

109 rranted as the decision to introduce protein conjugated vaccine in India is made.

110 previously recommended 7-valent pneumococcal conjugate vaccine, including serotype 19A, the predomina

111 e examine the effect of a glycolipid-peptide conjugate vaccine incorporating an NKT cell-activating g

112 A conjugate vaccine incorporating five serotypes (Ia, Ib,

113 Sustained Hib conjugate vaccine-induced immunity in children is depend

114 cocci, and investigated whether pneumococcal conjugate vaccine-induced serotype 6A and 6B antibodies

115 the Haemophilus influenzae serotype b (Hib) conjugate vaccine into national immunization has led to

116 Following 7-valent conjugate vaccine introduction in the United States in 2

117 of the present study show that the ADX40-Id conjugate vaccine is a potential candidate as a stand-al

118 cal proof of concept of a 4-valent O antigen conjugate vaccine is ongoing.

119 TT as a carrier protein in other conjugate vaccines is known to be immunogenic and genera

120 nization of young children with pneumococcal conjugate vaccine, it is unclear whether the high risk r

121 poteichoic acid, the (poly)glycerolphosphate conjugate vaccine itself exhibited no detectable inflamm

122 -Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled o

123 e availability of an affordable, multivalent conjugate vaccine may be important in future epidemic re

124 ellular immunity following immunization with conjugate vaccines may direct vaccine design and boostin

125 Glycolipid-peptide conjugate vaccines may prove useful for the prevention o

126 ces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into their routine infant immun

127 mAb could be used in combination with a METH-conjugate vaccine (MCV) to safely improve the overall qu

128 (+)-METH HSMO9] and its use to prepare METH-conjugated vaccines (MCV) from maleimide-activated prote

129 roduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac).

130 n meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to g

131 Our novel, highly immunogenic Abeta conjugate vaccine, MER5101, shows promise for improving

132 The introduction of pneumococcal conjugate vaccines necessitates continued monitoring of

133 use to synthesize MCV will be applicable for conjugated vaccines of small molecules and other substan

134 yse the effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in En

135 was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage

136 sease following introduction of pneumococcal conjugate vaccine (PCV) are attributable to the vaccine'

137 , among children immunized with pneumococcal conjugate vaccine (PCV) both before and after IPD, the p

138 Immunization schedules with pneumococcal conjugate vaccine (PCV) differ among countries regarding

139 30%-60% of episodes before the pneumococcal conjugate vaccine (PCV) era.

140 vestigated the impact of infant pneumococcal conjugate vaccine (PCV) immunization on pneumococcal col

141 The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries was enhan

142 untries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive p

143 Pneumococcal conjugate vaccine (PCV) is now recommended for use in ad

144 termine the effect of 13-valent pneumococcal conjugate vaccine (PCV) on colonization.

145 Pneumococcal conjugate vaccine (PCV) was introduced into Alberta, Can

146 all residents received 7-valent pneumococcal conjugate vaccine (PCV-7), while in another 10 villages

147 haride vaccine (PPV; n = 14) or pneumococcal conjugate vaccine (PCV; n = 11).

148 Pneumococci could evade pneumococcal conjugate vaccines (PCV) by modifying, mutating, or dele

149 full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness i

150 whether pneumococcal polysaccharide-protein conjugated vaccines (PCV), although highly effective in

151 razil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on n

152 Both the 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) induce immunologica

153 he immune response to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4 to 5 years la

154 , the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vacc

155 Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-val

156 ombined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysacc

157 T received 3 doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month intervals, a fourth

158 3, and 4 months of age, and the pneumococcal conjugate vaccine (PCV13) at 2, 4, and 12 months, all ad

159 The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population level is unc

160 cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) compared with 23-valent pneumo

161 The 13-valent pneumococcal conjugate vaccine (PCV13) has recently been approved for

162 (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010.

163 ted the efficacy of 13-valent polysaccharide conjugate vaccine (PCV13) in preventing first episodes o

164 and immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) in this population.

165 e introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant immuni

166 e switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13) occurred in June 2010.

167 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM

168 on the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal otitis.

169 The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes

170 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine (P

171 In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

172 In March 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced the seven-valent vacc

173 es, one or both isolates were a pneumococcal conjugate vaccine (PCV13) serotype.

174 The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include diseas

175 Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was inferred before licensure

176 In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine

177 P = 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

178 In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended i

179 The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to replace the 7-

180 or 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently reported as a use

181 013, a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended for immunocomp

182 e introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity increased in chi

183 capable of detecting 13-valent pneumococcal conjugate vaccine (PCV13)-associated serotypes.

184 types included in the 13-valent pneumococcal conjugate vaccine (PCV13).

185 14 weeks) and 13-valent pneumococcal CRM197-conjugate vaccine (PCV13; age 6/14 weeks and 9 months).

186 after the widespread use of the pneumococcal conjugate vaccine PCV7.

187 baseline (2000-2007), 7-valent pneumococcal conjugate vaccine (PCV7) (2008-2010), and PCV13 (2011-20

188 otypes associated with 7-valent pneumococcal conjugate vaccine (PCV7) accounted for 25% of UAD-positi

189 icensed to replace the 7-valent pneumococcal conjugate vaccine (PCV7) based on serological noninferio

190 a introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valen

191 the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumoc

192 Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced macrolide-resis

193 iatric introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, incidence of IPD among

194 ction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

195 in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 month

196 outh Africa introduced 7-valent pneumococcal conjugate vaccine (PCV7) in April 2009 using a 2 + 1 sch

197 he introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in September 2006 has markedly

198 lowing introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization prog

199 The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immuniz

200 mine the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal diseas

201 the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and th

202 otypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) transmitted by their mothers th

203 who were enrolled in a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

204 essed the impact of 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococcal nasopharyng

205 In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 with a t

206 In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and r

207 he introduction of seven-valent pneumococcal conjugate vaccine (PCV7) were associated with changes in

208 recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (

209 re the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease

210 after introduction of 7-valent pneumococcal conjugate vaccine (PCV7).

211 fter implementation of 7-valent pneumococcal conjugate vaccine (PCV7).

212 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by

213 duction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altere

214 The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are hi

215 ext of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13).

216 The 7-valent pneumococcal conjugated vaccine (PCV7) has affected the genetic popul

217 ect effects of pediatric use of pneumococcal conjugate vaccines (PCVs) affect rates of adult serotype

218 Pneumococcal conjugate vaccines (PCVs) are being used worldwide.

219 Pneumococcal conjugate vaccines (PCVs) are highly effective in preven

220 Pneumococcal conjugate vaccines (PCVs) are used in many low-income co

221 h, even though highly effective pneumococcal conjugate vaccines (PCVs) are used in national immunizat

222 Pneumococcal conjugate vaccines (PCVs) have been introduced worldwide

223 Pneumococcal conjugate vaccines (PCVs) have demonstrated efficacy aga

224 OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of v

225 Pneumococcal conjugate vaccines (PCVs) have substantially reduced mor

226 Pneumococcal conjugate vaccines (PCVs) have substantially reduced the

227 The use of pneumococcal conjugate vaccines (PCVs) in children has a strong indir

228 ciated with the introduction of pneumococcal conjugate vaccines (PCVs) in five countries in the Ameri

229 s available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries.

230 Use of pneumococcal conjugate vaccines (PCVs) in resource-poor countries has

231 Pneumococcal conjugate vaccines (PCVs) target only a few serotypes th

232 rends after the introduction of pneumococcal conjugate vaccines (PCVs).

233 Pneumococcal conjugated vaccines (PCVs) impact on complex otitis medi

234 Currently, the conjugate vaccine Pfs25-EPA/Alhydrogel is in Phase 1 cli

235 nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) on nasopharyngeal bacterial

236 Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infan

237 y 6- to 12-y-old children 6 y following MenC conjugate vaccine priming, before a booster of a combine

238 e critical steps toward reducing the cost of conjugate vaccine production, which will increase access

239 Meningococcal conjugate vaccines protect individuals directly, but can

240 y pathway for this new group A meningococcal conjugate vaccine proved to be a useful training opportu

241 Polysaccharide-conjugate vaccines provide protection against both invas

242 A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in

243 A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically fo

244 seria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was licensed for use in sub-S

245 with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African mening

246 The monovalent meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed for

247 able, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to

248 s in Europe and Africa ensured that the MenA conjugate vaccine (PsA-TT, MenAfriVac) was licensed by t

249 meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in I

250 ccal A polysaccharide-tetanus toxoid protein conjugate vaccine (PsA-TT, or MenAfriVac) was undertaken

251 group A (NmA) polysaccharide-tetanus toxoid conjugate vaccine, PsA-TT (MenAfriVac), designed specifi

252 A meningococcal group A conjugate vaccine, PsA-TT (MenAfriVac), developed throug

253 the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in 2010, we anal

254 introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in Africa exempl

255 In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), was introduced i

256 A group A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriVac), was introduced i

257 The group A meningococcal conjugate vaccine, PsA-TT, uses tetanus toxoid (TT) as a

258 A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was

259 d, worked to develop a group A meningococcal conjugate vaccine, PsA-TT.

260 In contrast, antibodies to the CP8-CRM conjugate vaccine reacted with CP8 and (to a lesser exte

261 PS conjugate vaccines recruit CD4(+) T cells via a carrier

262 The conjugate vaccine required aggregation of the protein to

263 NTS vaccines and the introduction of S Typhi conjugate vaccines should be considered for high-inciden

264 Finally, the conjugate vaccine showed immunogenicity and induced prot

265 y immunized with the (poly)glycerolphosphate conjugate vaccine showed rapid clearance of staphylococc

266 -response trials comparing free CPS with the conjugate vaccine showed that free CPS is nonimmunogenic

267 s, most notably with the advent of effective conjugate vaccines since the 1990s.

268 nd current candidate capsular polysaccharide conjugate vaccines target only a subset of these.

269 ed important opportunities for accessing new conjugate vaccine technology and know-how.

270 led up production of a group A meningococcal conjugate vaccine that used SIIL tetanus toxoid as the c

271 schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria toxoid as the pro

272 The methods of conjugation often produce conjugate vaccines that contain polysaccharides with sev

273 Remarkably, the conjugate vaccine, through aggregation of the protein an

274 ecific goal of developing an affordable MenA conjugate vaccine to eliminate MenA meningitis epidemics

275 rotein vaccine candidates as alternatives to conjugate vaccines to prevent non-serotype-specific S. p

276 We reanalyzed the 7-valent pneumococcal conjugate vaccine trial FinOM for prevention of acute ot

277 considered suggest that ceasing pneumococcal conjugate vaccine use would cause an increase in invasiv

278 sing in prevalence in the wake of widespread conjugate vaccine use, but no wciG-deficient variants ha

279 assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established human infection m

280 ar, the different approaches used to develop conjugate vaccines using peptide/proteins, carbohydrates

281 Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogen

282 n a tetravalent A/C/Y/W-135-DT meningococcal conjugate vaccine vial, or in a final formulated bulk, a

283 A single conjugate vaccine was created that elicited high levels

284 y options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive ev

285 A new group A meningococcal conjugate vaccine was developed to eliminate deadly meni

286 us exposure, vaccination with polysaccharide conjugate vaccine was highly effective, as indicated by

287 The group A meningococcal conjugate vaccine was named MenAfriVac, and is the first

288 A leading nicotine conjugate vaccine was only efficacious for one-third of

289 The new group A meningococcal conjugate vaccine was well received, with country covera

290 They confirmed that the development of conjugate vaccines was a priority and provided informati

291 e, using protein linked to a TLR7/8 agonist (conjugate vaccine), we investigated the functional prope

292 duce the next generation of more efficacious conjugate vaccines, we have explored a synthetic design

293 Several conjugate vaccines were developed to test these conclusi

294 The conjugate vaccine, which has been successful in reducing

295 t the capsule are protective, polysaccharide conjugate vaccines, which are constructed against the mo

296 at a synthetic (poly)glycerolphosphate-based conjugate vaccine will contribute to active protection a

297 Since the introduction of the pneumococcal conjugate vaccines with/without protein D of nontypeable

298 To evaluate if combining these antigens in a conjugate vaccine would be potentially efficacious, we c

299 s in Europe and Africa ensured that the MenA conjugate vaccine would meet all international standards

300 our collaborative efforts to develop a MenA conjugate vaccine yielded a safe and highly effective va